Findings

What do systematic reviews say?

9 questions · 9 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 22.2%GRADE not reported 2 · 22.2%Very low 4 · 44.4%Low 1 · 11.1%Moderate 0 · 0%High 0 · 0%

Rofecoxib vs naproxen

Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Low

Rofecoxib vs naproxen

Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain

The review found no eligible studies for this question.

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rofecoxib vs naproxen

Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain

The review found no eligible studies for this question.

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rofecoxib vs naproxen

Any adverse event · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 274 participants
Very low

Rofecoxib vs naproxen

Serious adverse event · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 310 participants
Very low

Rofecoxib vs naproxen

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 310 participants
Very low

Rofecoxib (oral, 50 mg on first day then 25 to 50 mg per day for 4 days) vs Tinidazole (1 g per day for 3 days)

Total effective rate at 4 days · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Rofecoxib (oral, 50 mg on first day then 25 to 50 mg per day for 4… showed no clear difference in total effective rate at 4 days compared with tinidazole (1 g per day for 3 days); GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
4 days
RR 1.17 [0.95, 1.43]
1 study · 60 participants
GRADE not reported

Rofecoxib (oral, 50 mg on first day then 25 to 50 mg per day for 4 days) vs Tinidazole (1 g per day for 3 days)

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
4 days
No adverse effects reported in translation.
1 study · 60 participants
GRADE not reported

Summary of findings table 6: Willow bark extract vs rofecoxib

Arhus Index Scale 0‐130 Pain VAS Scale 0‐10 · patients with chronic LBP

1 finding from 1 review

Herbal medicine for low‐back pain 2014 · Cochrane Headline outcomes only
no estimate extracted
228 participants
Very low